interstitial lung disease

Final analysis of RECAP, an open-label extension study of pirfenidone in patients with idiopathic pulmonary fibrosis (IPF)
Ulrich Costabel, Carlo Albera, Lisa Lancaster, Phillip Hormel, Henry Hulter, Paul Noble

European Respiratory Journal Sep 2016, 48 (suppl 60) OA1812; DOI: 10.1183/13993003.congress-2016.OA1812
Long-term safety of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF): Pooled analysis of 4 clinical trials
Paul Noble, Carlo Albera, Lisa Lancaster, Phillip Hormel, Henry Hulter, Ulrich Costabel

European Respiratory Journal Sep 2016, 48 (suppl 60) OA1808; DOI: 10.1183/13993003.congress-2016.OA1808
Diaphragmatic dysfunction evaluated by ultrasound correlates with dyspnea, exercise and quality of life in interstitial lung disease
Pauliane Santana, Letícia Cardenas, Jeferson Ferreira, Vinicius Iamonti, Ozires Ramos, Thomas Jaeger, Andre Albuquerque, Carlos Carvalho, Pedro Caruso

European Respiratory Journal Sep 2016, 48 (suppl 60) OA2011; DOI: 10.1183/13993003.congress-2016.OA2011
Effect of baseline composite physiologic index on benefit of nintedanib in IPF
Athol Wells, Jürgen Behr, Wibke Stansen, Susanne Stowasser, Toby Maher

European Respiratory Journal Sep 2016, 48 (suppl 60) OA1811; DOI: 10.1183/13993003.congress-2016.OA1811
Annual rate of FVC decline in patients with IPF treated with pirfenidone: Pooled analysis from 3 pivotal studies
Paul Noble, Carlo Albera, Willis Chou, Ulrich Costabel, Bann-mo Day, Ian Glaspole, Marilyn Glassberg, Lisa Lancaster, David Lederer, Steven Nathan, Carlos Pereira, John Stauffer, Jeffrey Swigris

European Respiratory Journal Sep 2016, 48 (suppl 60) OA1810; DOI: 10.1183/13993003.congress-2016.OA1810
Analysis of patients with idiopathic pulmonary fibrosis (IPF) with percent predicted forced vital capacity (FVC)‹50% treated with pirfenidone (PFD) in RECAP
Ulrich Costabel, Carlo Albera, Klaus-Uwe Kirchgaessler, Frank Gilberg, Ute Petzinger, Paul Noble

European Respiratory Journal Sep 2016, 48 (suppl 60) OA1813; DOI: 10.1183/13993003.congress-2016.OA1813
LATE-BREAKING ABSTRACT: Simtuzumab in idiopathic pulmonary fibrosis: Results of a randomized clinical trial
Ganesh Raghu, Kevin Brown, Harold Collard, David Lederer, Fernando Martinez, Paul Noble, Jin Woo Song, Athol Wells, Timothy Whelan, Emmanuel Moreau, Scott Patterson, Selina Bayly, Jason Chien, Jennifer Zhang, Thomas O'Riordan

European Respiratory Journal Sep 2016, 48 (suppl 60) OA1807; DOI: 10.1183/13993003.congress-2016.OA1807
Efficacy of total lung lavage in pulmonary alveolar proteinosis: A multicenter international study of GELF
Pierre Gay, Benoit Wallaert, Stefan Nowak, Jonas Yserbit, S. Anevlavis, C. Hermant, Alban Lovis, Olivier Menard, Bernard Maitre, Thomas Vandermoortel, Herve Dutau, Amandine Briault, Arnaud Bourdin, Marios Froudarakis, Jean-Michel Vergnon

European Respiratory Journal Sep 2016, 48 (suppl 60) OA3020; DOI: 10.1183/13993003.congress-2016.OA3020
Benefit of treatment with pirfenidone (PFD) persists over time in patients with idiopathic pulmonary fibrosis (IPF) with limited lung function impairment
Paul Noble, Carlo Albera, Klaus-Uwe Kirchgaessler, Frank Gilberg, Ute Petzinger, Ulrich Costabel

European Respiratory Journal Sep 2016, 48 (suppl 60) OA1809; DOI: 10.1183/13993003.congress-2016.OA1809
LATE-BREAKING ABSTRACT: Anti-fibrotic effects of nintedanib and pirfenidone in 2D versus 3D lung cultures
Mareike Lehmann, Lara Buhl, Darcy Wagner, Jürgen Behr, Michael Lindner, Melanie Königshoff

European Respiratory Journal Sep 2016, 48 (suppl 60) OA478; DOI: 10.1183/13993003.congress-2016.OA478

Main menu

User menu

Search

interstitial lung disease

Pages

Contact us